House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Suspected cancer: recognition and referral

NICE · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG12 provides symptom- and age-specific routes for investigating suspected cancer, with 2026 changes including age-based ovarian testing and unexplained weight-loss assessment. This focused selection emphasizes common referral triggers and safety netting. Referral thresholds support clinical judgement; a result below a threshold does not by itself exclude cancer. Recommendations apply according to relevant reproductive anatomy as well as age and symptoms.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognise respiratory, digestive and breast triggers

  • Use a suspected-cancer pathway for lung cancer when chest radiography suggests malignancy, or from age 40 with unexplained haemoptysis. From age 40, offer urgent chest radiography for at least two unexplained symptoms among cough, fatigue, breathlessness, chest pain, weight loss or appetite loss, or at least one if ever-smoked. [1]
  • Refer on a suspected-cancer pathway for oesophageal or stomach cancer with dysphagia, or from age 55 with weight loss plus upper abdominal pain, reflux or dyspepsia. These combined criteria should not be reduced to age or dyspepsia alone. [1]
  • For pancreatic cancer, refer on the suspected-cancer pathway from age 40 with jaundice. From age 60 with weight loss plus diarrhoea, back or abdominal pain, nausea, vomiting, constipation or new-onset diabetes, consider urgent CT, or ultrasound if CT is unavailable. [1]
  • Offer quantitative FIT for suspected colorectal cancer in adults with abdominal mass, altered bowel habit or iron-deficiency anaemia; from age 40 with unexplained weight loss and abdominal pain; under 50 with rectal bleeding plus unexplained pain or weight loss; from 50 with unexplained bleeding, pain or weight loss; or from 60 with anaemia without iron deficiency. [1]
  • For suspected colorectal cancer, refer adults with FIT at least 10 micrograms haemoglobin/g faeces. A lower result or unreturned sample requires safety netting; do not delay referral when continuing unexplained symptoms create strong concern. Rectal masses and unexplained anal masses or ulceration can proceed to referral consideration without FIT. [1]
  • Refer on a breast suspected-cancer pathway from age 30 with an unexplained lump, with or without pain, or from 50 with discharge, retraction or other concerning change in one nipple. Consider this pathway for suspicious skin changes or an unexplained axillary lump from 30; consider nonurgent referral for an unexplained lump below 30. [1]

Use the updated ovarian and endometrial pathways

  • For people with female reproductive organs, ascites or a pelvic/abdominal mass not obviously fibroids warrants a gynaecological suspected-cancer referral. Persistent or frequent bloating, early satiety/appetite loss, pelvic/abdominal pain or urinary urgency/frequency warrants ovarian testing, especially from 50 and when occurring more than 12 times monthly. [1]
  • With persistent ovarian-cancer symptoms and relevant reproductive anatomy at age 39 or under, do not rely on CA125 alone; consider urgent abdominal/pelvic ultrasound. If normal, investigate alternative causes and advise return if symptoms become more frequent or persistent and no other cause is found. [1]
  • With persistent ovarian-cancer symptoms and relevant reproductive anatomy from age 40, measure CA125. Arrange urgent abdominal/pelvic ultrasound at age-specific thresholds:40–49, ≥35; 50–59, ≥31; 60–69, ≥24; 70–79, ≥25; 80+, ≥31 IU/ml. Ultrasound suggesting ovarian cancer warrants suspected-cancer referral; below-threshold CA125 or normal ultrasound still requires alternative-cause assessment and safety netting. [1]
  • For unexplained postmenopausal bleeding not attributable to HRT, refer on an endometrial suspected-cancer pathway at age 55 or over and consider referral below 55. Unscheduled bleeding on HRT has a separate evidence-limited pathway; NICE signposts British Menopause Society guidance rather than applying these rules indiscriminately. [1]

Keep symptomatic testing distinct from screening

  • For people with a prostate, a malignant-feeling prostate on rectal examination warrants suspected-cancer referral. Consider PSA testing and rectal examination with lower urinary symptoms, erectile dysfunction or visible haematuria. [1]
  • With possible prostate-cancer symptoms, consider referral when PSA exceeds the age threshold:40–49, >2.5; 50–59, >3.5; 60–69, >4.5; 70–79, >6.5 micrograms/litre. Use judgement below 40 or above 79, and incorporate preferences and comorbidity. These are symptomatic-referral thresholds. [1]
  • From age 45, unexplained visible haematuria without UTI, or persistent/recurrent visible bleeding after successful UTI treatment, warrants bladder and renal suspected-cancer referral. For bladder cancer, also refer from 60 with unexplained nonvisible haematuria plus dysuria or a raised blood white-cell count. [1]

Assess suspicious lesions and neurological change

  • For suspected melanoma, refer when dermoscopy suggests melanoma or a suspicious pigmented lesion scores at least 3 on the weighted checklist: size change, irregular shape and irregular colour score2 each; diameter at least 7 mm, inflammation, oozing and altered sensation score1 each. Consider referral for suspected nodular melanoma even without pigment. [1]
  • Consider an oral suspected-cancer referral for unexplained oral ulceration lasting more than 3 weeks or a persistent unexplained neck lump. Lip/oral lumps or red or mixed red-white patches consistent with erythroplakia/erythroleukoplakia warrant consideration of urgent dental assessment; the dentist considers cancer referral for suspicious findings. [1]
  • For adults with progressive subacute loss of central neurological function, consider urgent brain MRI, or CT if MRI is contraindicated. For children or young people with newly abnormal cerebellar or other central neurological function, consider specialist assessment within 48 hours. [1]

Recognise haematological and childhood presentations

  • Consider a very urgent blood count for adult leukaemia with pallor, persistent fatigue, unexplained fever or persistent/recurrent infection, generalized lymphadenopathy, unexplained bruising/bleeding/petechiae or hepatosplenomegaly. Children and young people with unexplained petechiae or hepatosplenomegaly need immediate specialist assessment. [1]
  • From age 60 with persistent bone pain, especially back pain, or unexplained fracture, investigate myeloma with blood count, calcium, plasma viscosity or ESR, serum electrophoresis and serum free light chains. Use urine Bence–Jones testing if serum light chains are unavailable; refer if results suggest myeloma. [1]
  • Consider suspected-cancer referral for adult unexplained lymphadenopathy suggesting lymphoma, or unexplained splenomegaly for non-Hodgkin lymphoma; accompanying constitutional symptoms inform the decision. Children and young people with these presentations warrant consideration of specialist assessment within 48 hours. [1]
  • For an unexplained enlarging soft-tissue lump, consider urgent ultrasound in adults and very urgent ultrasound in children/young people. Suggestive ultrasound, or uncertain imaging with persistent concern, warrants consideration of cancer referral in adults and specialist assessment within 48 hours in children/young people. [1]
  • In children, a palpable abdominal mass or unexplained organ enlargement merits consideration of specialist assessment within 48 hours for neuroblastoma or Wilms tumour; unexplained visible haematuria also supports the Wilms pathway. Persistent parental concern can justify referral even when a benign cause appears most likely. [1]

Investigate nonspecific symptoms and close the loop

  • For unexplained weight loss greater than 5% within 6 months from age 60, assess additional findings and offer urgent investigation or a cancer/nonspecific-symptoms referral. Unexplained appetite loss also warrants assessment and an offered investigation/referral pathway; with deep-vein thrombosis, assess associated findings and consider such referral or investigation. [1]
  • Ensure test results are reviewed and acted on, with explicit ownership; chest radiography and faecal blood tests can be falsely negative. Consider planned or symptom-triggered review when cancer-associated symptoms do not meet referral criteria, explaining what changes require return. [1]
  • Explain that referral is to a cancer service while discussing alternative diagnoses. Seek specialist advice if referral is uncertain; after deciding to refer, send it within 1 working day and ensure missed appointments can be identified and followed up. [1]

Limitations and use

  • This selected summary does not reproduce every cancer-site trigger or the complete symptom-index tables. Omitted pathways include several genital, testicular, thyroid, skin and childhood tumour presentations; absence from this summary is not a reason to withhold referral.
  • These are NICE UK investigation and referral recommendations, not population-screening thresholds. Access arrangements and diagnostic targets require local adaptation in India.
  • Suspected-cancer referral, urgent investigation and immediate emergency care are distinct pathways. The guideline defines urgent as before two weeks and very urgent as within 48 hours; its suspected-cancer pathway targets diagnosis or exclusion within 28 days. Acute clinical instability requires its own emergency assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Suspected cancer: recognition and referral

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
23 June 2015
Publisher’s latest update
15 April 2026
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognise respiratory, digestive and breast triggers
  • Use the updated ovarian and endometrial pathways
  • Keep symptomatic testing distinct from screening
  • Assess suspicious lesions and neurological change
  • Recognise haematological and childhood presentations
  • Investigate nonspecific symptoms and close the loop
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House